|
|
|
|
|
Jan 7, 2009: Orphagen Pharmaceuticals Announces Collaboration and License Agreement with Japan Tobacco, Inc. September 1, 2007: National Institutes of Health (NIH) Funds Discovery Research for Treatment of Rheumatoid Arthritis at Orphagen Pharmaceuticals. June 1, 2007: Orphagen Pharmaceuticals is Awarded a Phase 1 SBIR Grant for Discovery of Novel Therapeutics for Treatment of MS. February 16, 2007: Len Post joins the Orphagen Board of Directors. September 23, 2005: National Institutes of Health awards Orphagen $460,339 to investigate novel treatments for sleep disorders. May 26, 2005: Orphagen is awarded a Small Business
Investigative Research (SBIR) Phase I grant for drug discovery in the area of
metabolic disease. February 1, 2010: Orphagen is awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders
|
|
|
